AnGes, Inc.

4563

JP3127700007

Biotechnology & Medical Research

Market Closed - Japan Exchange Other stock markets 07:00:00 18/07/2024 BST			5-day change	1st Jan Change
48 ^JPY	+6.67%		+11.63%	-33.33%

01-19	Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	MT
01-18	Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	CI

AnGes MG, Inc. announced that it has received ¥22.4 million in funding from Credit Suisse Securities Limited, Investment Arm

January 03, 2017

On January 4, 2017, AnGes MG, Inc. (TSE:4563) closed the transaction.

Latest news about AnGes, Inc.

Eiger BioPharmaceuticals Gets Marketing Approval for Treatment of Ultra-Rare Genetic Disease	01-19	MT
Eiger BioPharmaceuticals, Inc. and Partner, AnGes, Inc. Receive Approval for Zokinvy for Hutchinson- Gilford Progeria Syndrome and Processing-Deficient Progeroid Laminopathies in Japan	01-18	CI
Vasomune Therapeutics, Inc. and AnGes Announce Drug Candidate AV-001 Receives Positive Recommendation from the IDSMB for AV001-004 Phase 2a Study	11-14	CI
Tupperware Brands Corporation : Plastic is fantastic	08/08/23
AnGes, Inc. announced that it has received Â¥8.481467 million in funding	11/07/23	CI
AnGes, Inc. announced that it expects to receive Â¥8.481467 million in funding	25/06/23	CI
Forex: A dead cat bounce?	15/05/23
AnGes, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	10/05/23	CI
AnGes, Inc. Auditor Raises 'Going Concern' Doubt	30/03/23	CI
Mybiotics Pharma LTD announced that it has received $0.5 million in funding from AnGes, Inc.	27/11/22	CI
Eiger Biopharmaceuticals Inc. and AnGes Inc. Announce Exclusive Partnership for Regulatory Approval and Commercialization of Zokinvy® in Japan	10/05/22	CI
AnGes, Inc.(TSE:4563) dropped from S&P Japan 500	22/03/22	CI
Etsy, Inc: Great opportunity or distorted reality?	31/01/22
AnGes, Inc. Announces Results of Phase 1/2 and Phase 2/3 Clinical Trials	05/11/21	CI
AnGes, Inc. announced that it has received ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm	23/03/21	CI
Meiji : Japan's KM Biologics begins clinical trial of COVID-19 vaccine candidate	22/03/21	RE
AnGes, Inc. announced that it expects to receive ¥98.2 million in funding from Cantor Fitzgerald & Co, Investment Arm	07/03/21	CI
AnGes, Inc. completed the acquisition of Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others.	14/12/20	CI
AnGes : Japan's AnGes begins phase 2/3 clinical trial of DNA-based COVID-19 vaccine	08/12/20	RE
AnGes, Inc. signed an agreement to acquire Emendo Bio, Inc. from Orbimed Israel Partners II, L.P., OrbiMed Private Investments VI, LP, managed by OrbiMed Advisors LLC, Takeda Ventures, Inc. and others for approximately $110 million.	08/11/20	CI
Shionogi : REFILE-Japan's Shionogi readies COVID-19 vaccine for December trial- CEO	29/10/20	RE
AnGes, Inc. and Er-Kim Enter into an Agreement for the Commercialization of Collategene® in Turkey	15/10/20	CI
AnGes, Inc.(TSE:4563) added to S&P Japan 500	23/09/20	CI
Factbox: The race for a coronavirus vaccine	15/09/20	RE
AnGes, Inc. and Brickell Biotech, Inc. Announce Collaboration Agreement for the Development of A Novel DNA Vaccine Candidate for COVID-19 in the U.S	08/09/20	CI

AnGes, Inc., formerly AnGes MG, Inc., is a Japan-based company mainly engaged in the development of genetic medicines. The Company is involved in the development of hepatocyte growth factor (HGF) genetic medicines, NF-KB decoy oligo and hemagglutinating virus of Japan envelope (HVJ-E) non-viral vector, among others. As of December 31, 2012, the Company had four consolidated subsidiaries. On January 31, 2013, the Company sold a 95.3% stake of a Osaka-based subsidiary to ISHIHARA SANGYO KAISHA LTD.

Sector

Biotechnology & Medical Research

Calendar

08/08/2024 - Q2 2024 Earnings Release

More about the company

	1st Jan change	Capi.
ANGES, INC.	-33.33%	65.8M
VERTEX PHARMACEUTICALS INCORPORATED	+20.03%	126B
REGENERON PHARMACEUTICALS, INC.	+23.61%	117B
ARGENX SE	+23.03%	27.52B
BIONTECH SE	-18.07%	20.87B
GENMAB A/S	-13.94%	17.01B
BEIGENE, LTD.	-14.81%	16.26B
NEUROCRINE BIOSCIENCES, INC.	+9.78%	14.56B
WUXI APPTEC CO., LTD.	-46.10%	15.09B
SAREPTA THERAPEUTICS, INC.	+52.34%	13.89B

Bio Therapeutic Drugs

AnGes, Inc.

Equities

4563

JP3127700007

Biotechnology & Medical Research

AnGes MG, Inc. announced that it has received ¥22.4 million in funding from Credit Suisse Securities Limited, Investment Arm

Latest news about AnGes, Inc.

Chart AnGes, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Bio Therapeutic Drugs